Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin growth accelerates

Q2 FY2026 selling, general & admin of $662.1M rose 4.4% year over year, ahead of the -1.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 2.2% from the prior quarter. Over 3 fiscal years it compounded at +8.5% a year.

Context

  • Selling, general & admin amounted to 18.8% of revenue in FY2025, down 2.0 pp from a year earlier.
  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 19 analysts of $3.3B (+22.0%) for the fiscal year ending Dec 2026, a step up from the -8.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$662.1M+2.2% QoQ
Last fiscal yearDec 2025
$2.7B-8.6% YoY
LTMJun 2026
$2.74B-1.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.4%+22.3%+17.9 pp
1 year-8.6%+22.0%+30.6 pp
3-year CAGR+8.5%+12.0%+3.5 pp
5-year CAGR+10.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
2.7B USD
Year-over-year change
-8.6%
4-year CAGR
+10.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 selling, general & admin of $2.74B is the 5th highest of the 9 companies compared; the peer median is $4.53B.
  • Its year-over-year change of -1.1% is the lowest of 8, against a peer median of +1.8%.
  • Selling, general & admin amounts to 17.7% of revenue for REGN, versus a peer median of 24.8%.
REGN Competitors Peer median
Selling, General & Admin for REGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$20.52B +0.5%+4.5%33.0%
NVSNovartis AGLTM Jun 2026$13.13B -0.1%+3.0%23.6%
AMGNAmgen Inc.LTM Jun 2026$7B +1.8%+9.2%18.4%
GILDGilead Sciences, Inc.LTM Jun 2026$6.46B +9.6%+0.2%21.2%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$2.74B -1.1%+8.5%17.7%
BIIBBiogen Inc.LTM Jun 2026$2.59B +7.6%+0.3%26.1%
GMABGenmab A/SLTM Jun 2026$726.99M —-39.2%17.6%
OCULOcular Therapeutix, Inc.LTM Mar 2026$124.38M +14.7%+17.9%239.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$53.04M +1.3%-5.0%696.5%
Peer median (excluding REGN) $4.53B+1.8%+1.6%24.8%

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue16.07B12.17B13.12B14.2B14.34B
Cost of Revenue2.72B1.71B2.24B1.97B2.1B
Gross Profit13.35B10.47B10.87B12.23B12.24B
Gross Margin83.1%86.0%82.9%86.1%85.4%
Research & Development2.62B3.06B3.99B5.23B5.85B
Selling, General & Admin1.82B2.12B2.54B2.95B2.7B
Operating Expenses4.4B5.08B6.52B8.24B8.66B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
EBITDA9.67B5.26B4.69B5.32B5.82B
EBITDA Margin60.2%43.2%35.8%37.4%40.6%
Operating Income8.95B5.39B4.35B3.99B3.58B
Operating Margin55.7%44.2%33.2%28.1%24.9%
Interest Income0160.1M495.9M711.4M716.8M
Interest Expense57.3M59.4M73M55.2M43.8M
Other Income / Expenses379M(526.8M)(149.3M)789.2M1.65B
Income Before Tax9.33B4.86B4.2B4.78B5.23B
Pre-Tax Margin58.0%39.9%32.0%33.7%36.5%
Income Tax Expense1.25B520.4M245.7M367.3M725.8M
Net Income8.08B4.34B3.95B4.41B4.5B
Net Margin50.2%35.6%30.1%31.1%31.4%
EPS (Basic)76.4040.5137.0540.9043.07
EPS (Diluted)71.9738.2234.7738.3441.48
Weighted Avg Shares105.7M107.1M106.7M107.9M104.6M
Weighted Avg Shares (Diluted)112.2M113.5M113.7M115.1M108.6M

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.